Skip to main content

Table 1 Clinical characteristics of HER2-positive breast cancer patients and the univariate analysis of predictive biomarkers of the response to anthracyclines

From: Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy

Factors Number of patients (%) Clinical response Pathological response
   Stable disease + progressive disease Partial response + complete response P Complete pathological response Incomplete pathological response P
Age
45 years 34 (30%) 10 24 0.975 3 31 0.450
≥45 years 79 (70%) 23 56   11 68  
Menopausal status
Postmenopausal 69 (61%) 20 49 0.949 7 62 0.364
Premenopausal 44 (39%) 13 31   7 37  
Regimen
 CEF 55 (49%) 15 40 0.660 9 46 0.212
 NE 58 (51%) 18 40   5 53  
Tumor size
≤5 cm 46 (41%) 21 25 0.001 4 42 0.323
>5 cm 67 (59%) 12 55   10 57  
Lymph node status
0 43 (38%) - - - - - -
1 to 3 31 (27%) - - - - - -
4 to 9 25 (22%) - - - - - -
≥10 14 (13%) - - - - - -
Pre-estrogen receptor
Negative 78 (69%) 21 57 0.426 10 68 0.835
Positive 35 (31%) 12 23   4 31  
Pre-progesterone receptor
Negative 83 (73%) 24 59 0.911 9 74 0.518
Positive 30 (27%) 9 21   5 25  
Pre-pMAPK
Negative 34 (30%) 13 21 0.166 8 26 0.855
Positive 79 (70%) 20 59   6 73  
Pre-pAKT
Negative 30 (27%) 14 16 0.014 4 26 0.855
Positive 83 (73%) 19 64   10 73  
Pre-PTEN
Negative 40 (35%) 13 27 0.568 5 35 0.979
Positive 73 (65%) 20 53   9 64  
Pre-P27
Negative 35 (31%) 15 20 0.432 5 40 0.737
Positive 68 (69%) 18 50   9 59  
Pre-IGF-1R
Negative 47 (42%) 12 35 0.469 5 42 0.634
Positive 66 (58%) 21 45   9 57  
Pre-cyclinD1
Negative 42 (37%) 14 28 0.458 4 38 0.477
Positive 71 (63%) 19 52   10 61  
Pre-Ki67
Negative 43 (38%) 15 28 0.298 2 41 0.076
Positive 70 (62%) 18 52   12 58  
  1. IGF-1R, insulin-like growth factor 1 receptor; pAKT, phosphorylated AkT; pMAPK, phosphorylated mitogen-activated protein kinase.